Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 0.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 37,200 shares of the medical research company’s stock after acquiring an additional 205 shares during the period. Nisa Investment Advisors LLC’s holdings in Exact Sciences were worth $2,752,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in EXAS. American Century Companies Inc. boosted its holdings in shares of Exact Sciences by 16.5% during the first quarter. American Century Companies Inc. now owns 5,760 shares of the medical research company’s stock worth $403,000 after purchasing an additional 817 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Exact Sciences during the first quarter worth $742,000. Panagora Asset Management Inc. boosted its holdings in shares of Exact Sciences by 4.6% during the first quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company’s stock worth $509,000 after purchasing an additional 323 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Exact Sciences by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 448,640 shares of the medical research company’s stock worth $31,377,000 after purchasing an additional 53,454 shares during the last quarter. Finally, Vontobel Holding Ltd. boosted its holdings in shares of Exact Sciences by 143.5% during the first quarter. Vontobel Holding Ltd. now owns 22,230 shares of the medical research company’s stock worth $1,585,000 after purchasing an additional 13,102 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insider Buying and Selling

In related news, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $70.00, for a total value of $140,000.00. Following the transaction, the executive vice president now owns 71,787 shares in the company, valued at $5,025,090. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Exact Sciences news, insider Jacob A. Orville sold 966 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $59,341.38. Following the sale, the insider now owns 7,488 shares in the company, valued at $459,987.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sarah Condella sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the sale, the executive vice president now owns 71,787 shares in the company, valued at approximately $5,025,090. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,113 shares of company stock worth $4,165,273. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EXAS shares. Canaccord Genuity Group lowered their price target on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Citigroup reissued a “buy” rating and set a $100.00 price target on shares of Exact Sciences in a research report on Wednesday, April 3rd. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a research report on Tuesday, January 2nd. Finally, TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $97.44.

Exact Sciences Trading Down 2.2 %

Shares of EXAS opened at $71.34 on Friday. The stock’s 50-day moving average is $63.28 and its two-hundred day moving average is $65.21. The stock has a market cap of $12.95 billion, a PE ratio of -62.58 and a beta of 1.25. Exact Sciences Co. has a 12 month low of $56.05 and a 12 month high of $100.77. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The business had revenue of $646.89 million for the quarter, compared to analysts’ expectations of $638.83 million. During the same quarter in the previous year, the firm posted ($0.72) earnings per share. The company’s revenue was up 17.0% compared to the same quarter last year. Equities analysts forecast that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.